Detalhe da pesquisa
1.
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 95(5): 410-418, 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37940409
2.
Deeply 3D-T1-TFE hypointense voxels are characteristic of phase-rim lesions in multiple sclerosis.
Eur Radiol
; 34(2): 1337-1345, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-37278854
3.
Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases.
Headache
; 63(4): 559-564, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-37036126
4.
Influence of Cardiovascular Risk Factors in Early Relapsing-Remitting Multiple Sclerosis: A Retrospective Analysis.
Eur Neurol
; 86(1): 73-77, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36470228
5.
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Eur Neurol
; 83(1): 25-33, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32187609
6.
Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis.
Int J Mol Sci
; 21(22)2020 Nov 17.
Artigo
Inglês
| MEDLINE | ID: mdl-33213069
7.
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.
Mult Scler
; 24(14): 1843-1851, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28984163
8.
Feasibility and Effects of Structured Physical Exercise Interventions in Adults with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.
J Sports Sci Med
; 17(3): 426-436, 2018 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-30116116
9.
Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.
Clin Immunol
; 171: 18-24, 2016 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-27496090
10.
Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.
Mult Scler
; 22(3): 312-9, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26209592
11.
Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
Mult Scler
; 22(6): 741-52, 2016 05.
Artigo
Inglês
| MEDLINE | ID: mdl-26362897
12.
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Mult Scler
; 21(5): 550-61, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25732842
13.
Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
Eur Neurol
; 73(3-4): 220-229, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25792347
14.
Etiologic spectrum and prognosis of longitudinally extensive transverse myelopathies.
Eur Neurol
; 72(1-2): 86-94, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24942967
15.
The T1-dark-rim: A novel imaging sign for detecting smoldering inflammation in multiple sclerosis.
Eur J Radiol
; 173: 111358, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38340569
16.
Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
J Neurol
; 271(4): 1599-1609, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38085343
17.
Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series.
BMC Neurol
; 13: 135, 2013 Oct 03.
Artigo
Inglês
| MEDLINE | ID: mdl-24090445
18.
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
J Neurol
; 270(5): 2559-2566, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-36913038
19.
Kappa free light chains index in multiple sclerosis very long-term prognosis.
Front Immunol
; 14: 1223514, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37885887
20.
Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis.
Brain Commun
; 5(2): fcad109, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37091585